Semaglutide for Post-Menopause Weight Gain
GLP-1 medications help overcome hormonal metabolic slowdown. Semaglutide (Wegovy/Ozempic) is a GLP-1 receptor agonist shown to produce 15% average body weight loss in clinical trials.
How Semaglutide Helps with Post-Menopause Weight Gain
Semaglutide mimics the GLP-1 hormone to reduce appetite and slow stomach emptying, leading to significant weight loss. For patients with post-menopause weight gain, this weight loss translates to meaningful improvements in condition-specific outcomes.
GLP-1 medications help overcome hormonal metabolic slowdown. The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly produces an average weight loss of 15% of body weight over 68 weeks, with additional benefits for metabolic health markers.
Clinical Evidence for Post-Menopause Weight Gain
Post-Menopause Weight Gain affects Affects most post-menopausal women. Research shows that GLP-1 medications like semaglutide address both the weight component and the underlying metabolic dysfunction associated with post-menopause weight gain. Patients with this condition often see compounding benefits from weight loss, including improved energy, mobility, and overall quality of life.
Semaglutide Dosing for Post-Menopause Weight Gain
Semaglutide is taken as a once-weekly subcutaneous injection. The standard titration starts at 0.25mg and gradually increases to the maintenance dose of 2.4mg over 16-20 weeks. Dosing is the same regardless of the indication — your provider will monitor your response and adjust timing as needed.
Cost of Semaglutide for Post-Menopause Weight Gain
Compounded semaglutide costs $149-399/month through telehealth providers. Brand-name Wegovy costs $1,300+/month without insurance. Many patients with post-menopause weight gain have associated comorbidities that improve insurance coverage chances.